The estimated Net Worth of Ronald B Sr Kalich is at least $1.67 Milión dollars as of 27 December 2023. Mr. Kalich owns over 3,932 units of Surmodics stock worth over $1,511,493 and over the last 11 years he sold SRDX stock worth over $0. In addition, he makes $156,000 as Independent Director at Surmodics.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Kalich SRDX stock SEC Form 4 insiders trading
Ronald has made over 4 trades of the Surmodics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 3,932 units of SRDX stock worth $94,171 on 27 December 2023.
The largest trade he's ever made was exercising 4,430 units of Surmodics stock on 6 August 2021 worth over $94,403. On average, Ronald trades about 351 units every 22 days since 2014. As of 27 December 2023 he still owns at least 38,529 units of Surmodics stock.
You can see the complete history of Mr. Kalich stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ronald Kalich biography
Ronald B. Kalich Sr. serves as Independent Director of the Company. Mr. Kalich has been a private investor since 2007. Previously, from 2000 to 2007, he served as a Director and as President and Chief Executive Officer of FastenTech, Inc., a provider of highly engineered aerospace-grade, specialized and application-specific components. From 1999 to 2000, he served as President and Chief Executive Officer of National-Standard Company, a manufacturer and distributor of wire and wire-related products. From 1994 to 1999, he served as President and Chief Executive Officer of Getz Bro’s. & Co., Inc., a provider of healthcare, consumer, chemicals, and food processing products. He is also a past Chairman and Director of Arizant, Inc. (from 2005 to 2010).
What is the salary of Ronald Kalich?
As the Independent Director of Surmodics, the total compensation of Ronald Kalich at Surmodics is $156,000. There are 13 executives at Surmodics getting paid more, with Gary Maharaj having the highest compensation of $2,343,630.
How old is Ronald Kalich?
Ronald Kalich is 72, he's been the Independent Director of Surmodics since 2014. There are 1 older and 19 younger executives at Surmodics. The oldest executive at Surmodics, Inc. is David Dantzker, 76, who is the Independent Director.
What's Ronald Kalich's mailing address?
Ronald's mailing address filed with the SEC is 9924, West 74th Street, Eden Prairie, Hennepin County, Minnesota, 55344, United States of America.
Insiders trading at Surmodics
Over the last 21 years, insiders at Surmodics have traded over $26,204,565 worth of Surmodics stock and bought 19,725 units worth $436,251 . The most active insiders traders include Jeffrey C Smith, Gary R Maharaj a Value Lp Starboard Value Gp.... On average, Surmodics executives and independent directors trade stock every 34 days with the average trade being worth of $415,014. The most recent stock trade was executed by Joseph J. Stich on 21 August 2024, trading 21,285 units of SRDX stock currently worth $706,662.
What does Surmodics do?
surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. throughout its transformation, surmodics’ mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges.
What does Surmodics's logo look like?
Complete history of Mr. Kalich stock trades at Surmodics
Surmodics executives and stock owners
Surmodics executives and other stock owners filed with the SEC include:
-
Gary Maharaj,
President, Chief Executive Officer, Director -
Gary R. Maharaj,
CEO, Pres & Director -
Teri Sides,
Senior Vice President, Chief Marketing Officer -
Charles Olson,
Senior Vice President of Commercial and Business Development, Medical Devices -
Gregg Sutton,
Vice President - Research and Development, Medical Devices -
Thomas Greaney,
Chief Operating Officer, Medical Devices -
Timothy Arens,
Chief Financial Officer, Vice President - Finance -
Joseph Stich,
Vice President, General Manager - In Vitro Diagnostics -
Gordon S. Weber,
Sr. VP of Legal, Gen. Counsel & Sec. -
Timothy J. Arens,
Sr. VP of Fin. & Information Technology and CFO -
Joseph J. Stich,
Sr. VP and GM of HR & In Vitro Diagnostics -
Teryl L. W. Sides,
Sr. VP of Product Devel. & Chief Marketing Officer -
Susan Knight,
Non-Executive Independent Chairman of the Board -
Ronald Kalich,
Independent Director -
David Dantzker,
Independent Director -
Jose Bedoya,
Independent Director -
Shawn McCormick,
Independent Director -
Lisa Heine,
Independent Director -
Nusrath Sultana,
Vice President - Clinical Affairs -
Gordon Weber,
Senior Vice President - Legal, General Counsel, Secretary -
Gregg S. Sutton,
VP of R&D - Medical Devices -
Charles W. Olson,
Sr. VP of Commercial & Bus. Devel. of Medical Devices -
John D. Manders,
Corp. Controller & Principal Accounting Officer -
Lise W Duran,
VP Product Development -
Andrew D. C. La Frence,
VP of Finance & CFO -
Amy E. Seibert,
Principal Accounting Officer -
Michael J Shoup,
Vice President -
Douglas P Astry,
General Manager -
Aron B Anderson,
VP & Chief Scientific Officer -
John C. Middleton,
VP, Drug Del, Product Dev -
Brian L Robey,
Vice President -
Paul A Lopez,
Vice President -
Bruce Barclay,
President & COO -
John D. Manders,
Corporate Controller -
Steven J Keough,
VP & Chief IP Counsel -
Peter L Ginsberg,
Vice President -
Bryan K Phillips,
SVP, Gen Counsel & Secretary -
Kendrick B Melrose,
Director -
David A Koch,
Director -
Dale R Olseth,
Chairman and CEO -
Loren R Miller,
Vice President and Controller -
David S Wood,
VP & GM - Drug Del. Bus. Unit -
Patrick E Guire,
Senior Vice President -
Gregory T Yung,
VP Sales & Business Developmen -
Ronald F Ofstead,
VP Chemistry Development -
Richard C Carlson,
VP of Strategic Planning -
Jane M Nichols,
Vice President Marketing -
Marie J Versen,
Vice President -
John W Benson,
Director -
Mary K Brainerd,
Director -
Mark A. Lehman,
Treasurer -
Scott R. Ward,
Director -
Gerald B Fischer,
Director -
Timothy S Nelson,
Director -
Robert C Buhrmaster,
Director -
Eugene C. Rusch,
VP, Manufacturing -
Value Lp Starboard Value Gp...,
-
Philip D Ankeny,
Chief Financial Officer -
Jeffrey C Smith,
Director -
John A Meslow,
Director -
Jan M Webster,
Vice President, HR -
Arthur J Tipton,
Vice President -
Kenneth H Keller,
Director